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ABSTRACT  
Epidemiological studies suggest that fruits and vegetables may play a role in promoting bone growth 
and preventing age-related bone loss, attributable, at least in part, to phytochemicals such as flavonoids 
stimulating osteoblastogenesis. Through systematically screening the effect of flavonoids on the 
osteogenic differentiation of human mesenchymal stem cells in vitro, and correlating activity with 
chemical structure using comparative molecular field analysis (CoMFA), we have successfully 
identified important structural features which relate to their activity, as well as reliably predicting the 
activity of compounds with unknown activity. Contour maps emphasised the importance of 
electronegativity, steric bulk, and a 2-C3-C double bond at the flavonoid C-ring, as well as overall 
electropositivity and reduced steric bulk at the flavonoid B-ring. These results support a role for certain 
flavonoids in promoting osteogenic differentiation, thus their potential for preventing skeletal 
deterioration, as well as providing a foundation for the lead optimisation of novel bone anabolics. 
  
Bone remodelling is a highly dynamic process with approximately 5% of cortical and 20% of 
trabecular bone turned over annually.1 Skeletal integrity is dependent on the balance between 
osteoclastic-resorption and osteoblastic-formation of bone during cycles of remodelling, however this 
balance is lost with age. Trabecular bone loss is evident from the age of thirty,2 and by the age of fifty, 
up to 42% of total lifetime trabecular bone is lost.3 Contributing to this imbalance is a reduction in the 
level of bone formation during remodelling cycles, thought to occur as early as twenty years of age,4 
and is partly associated with reduced osteoblast differentiation and deposition of matrix components.5 
Preventative intervention strategies are therefore paramount for maintaining skeletal homeostasis, and 
thus life-long skeletal health.   
Epidemiological evidence suggests a positive association between fruit and vegetable intake and the 
accrual and maintenance of bone mass.6 Although the exact role(s) of fruit and vegetables remain 
unclear, much evidence from in vitro and in vivo studies suggest that flavonoids and related dietary 
phytochemicals could play an important role in supporting skeletal homeostasis via direct actions on 
osteoclasts and osteoblasts. The flavonols quercetin and kaempferol have gained considerable attention, 
with in vitro reports of their anti-osteoclastogenic activity,7-9 and ability of both quercetin10, 11 and 
kaempferol10-14 to promote osteoblast differentiation and function in several in vitro osteogenesis 
models. These observations are reinforced in vivo where complete recovery of ovariectomy-induced 
bone loss was observed following rutin (quercetin-3-rutinoside) supplementation in ovariectomised 
(OVX)-rats,15 and quercetin in OVX-mice,16 the latter of these studies associating the outcome 
predominantly with quercetin promoting bone formation. Osteogenic transplant studies also highlight 
the bone-anabolic properties of quercetin; promoting engraftment and bone formation in calvarial 
defect models.10, 17 Similarly, kaempferol has been demonstrated to protect against OVX-induced bone 
loss in rats, both by reducing the rate of skeletal turnover, and by increasing bone forming capacity; 
with a greater number of osteoprogenitor cells in bone marrow examined ex-vivo.13 Further to this, 
  
kaempferol injection into the calvarial periosteum of newborn rats has been shown to promote 
osteogenesis.18 These studies are further supported by the bone anabolic effects of kaempferol- and 
quercetin-rich Ginkgo biloba in rat models of OVX- and glucocorticoid-induced osteoporosis.19-21 
Collectively, a convincing argument exists for kaempferol and quercetin’s potential to support skeletal 
homeostasis via anti-osteoclastogenic and pro-osteogenic effects. Less attention however has focussed 
on other flavonols, of which there are over 600.22 
Alongside flavonols, flavanones have attracted attention due to the positive effects of a hesperetin 
glycoside-enriched diet on bone health in OVX-mice,23 OVX-rats,24, 25 and healthy young rats,25 with 
reports of supressed osteoclast number and bone turnover, and promotion of osteoblastic activity. 
Certain flavones26, 27 and flavanols28 have also been seen to have the potential to influence bone health 
in vivo, adding to the weight of literature exclaiming flavonoids as possible therapeutic agents for the 
prevention of bone thinning. Although a compelling argument exists for certain flavonoids exerting 
bone-anabolic effects, the wide-ranging in vitro models of osteogenesis examined and concentrations 
tested (Table S1, Supporting Information), make identifying which flavonoids have the greatest effects, 
and the structural basis for such activity difficult. Moreover, results using animal cells and transformed 
cell lines may be influenced by interspecies variation29 and variable phenotypic profiles 30 respectively. 
Thus we investigated the influence of flavonoids and related dietary phytochemicals on the osteogenic 
differentiation of primary human bone marrow-derived mesenchymal stem cells (hMSCs), the common 
precursor of the osteogenic lineage. 
We report the differential effects of a panel of 21 flavonoids and related phytochemicals, spanning 
the major flavonoid subclasses, on osteogenic differentiation within hMSC cultures. Using alkaline 
phosphatase (ALP) activity, an established osteogenic marker expressed between the late 
osteoprogenitor and preosteoblast stages of differentiation31, 32 we have employed three-dimensional 
quantitative structure activity relationship (3D QSAR) modelling with comparative molecular field 
  
analysis (CoMFA) to relate the observed pharmacological activity of these compounds to their 
chemical structures. 
Here we describe, for the first time, the effects of multiple flavonoids on the osteogenic 
differentiation of hMSCs, and discuss the structural basis for their activity. Briefly, seven flavonols 
(tamarixetin, kaempferide, kaempferol, galangin, quercetin, fisetin, and isorhamnetin) and two 
flavanones (hesperetin and naringenin) stimulated osteogenic differentiation of hMSCs. CoMFA 
contour maps emphasised the importance of electronegativity, steric bulk, and a 2-C3-C double bond 
at the flavonoid C-ring, as well as overall electropositivity and reduced steric bulk at the flavonoid B-
ring. 
 
RESULTS AND DISCUSSION 
     The Effect of Flavonoids on the Osteogenic Differentiation of hMSCs. Twenty-one flavonoids, 
and related dietary compounds (Figure 1), were screened for effects on osteogenic differentiation, using 
ALP activity as a marker of osteogenic differentiation (Figure 2). 
No flavonol increased ALP activity compared to the vehicle control (VC) following 1 µM treatment; 
significant increases were observed following 5 and 10 µM treatments with all flavonols except 
myricetin (7). 5 µM treatment with active flavonols increased ALP activity to approximate levels of 
between 2.37- and 1.52-fold compared to VC in the following order of magnitude: kaempferol (2) > 
tamarixetin (1) > quercetin (4) > fisetin (5) > galangin (3) > isorhamnetin (6). The order of magnitude 
was slightly different following 10 µM treatment (tamarixetin (1) > kaempferol (2) > galangin (3) > 
quercetin (4) > fisetin (5) > isorhamnetin (6)) with increases of between 3.01- and 1.32-fold over the 
VC; only tamarixetin (1), kaempferol (2) and galangin (3) induced a dose-dependent response between 
5 and 10 µM. In contrast to other flavonols tested, at 5 and 10 µM, myricetin (7) significantly reduced 
ALP activity by approximately 0.74- and 0.62-fold of the VC.   
  
 
# Compound R1 R2 R3 R4 R5 R6 
1 tamarixetin OH OH OH OH OCH3 H 
2 kaempferol OH OH OH H OH H 
3 galangin OH OH OH H H H 
4 quercetin OH OH OH OH OH H 
5 fisetin OH H OH OH OH H 
6 isorhamnetin OH OH OH OCH3 OH H 
7 myricetin OH OH OH OH OH OH 
8 hesperetin - OH OH OH OCH3 H 
9 naringenin - OH OH H OH H 
10 eriodictyol - OH OH OH OH H 
11 homoeriodictyol - OH OH OCH3 OH H 
12 diosmetin H OH OH OH OCH3 H 
13 apigenin H OH OH H OH H 
14 flavone H H H H H H 
15 luteolin H OH OH OH OH H 
16 epicatechin (2R,3R) OH OH OH OH OH H 
17 catechin (2R,3S) OH OH OH OH OH H 
18 EGCG (2R,3R) Gal OH OH OH OH OH 
19 phloretin - OH OH H OH H 
20 taxifolin (2R,3R) OH OH OH OH OH H 
21 resveratrol - OH OH H OH H 
 
Figure 1. Structure of compounds screened in the model of osteoblast differentiation. Compounds are 
numbered 1 to 21 and their respective substituents (R-groups) are highlighted in the table. Numbers 
within skeletal structures represent atom nomenclature. 
   
No flavanone significantly increased ALP activity above the VC following 1 or 5 µM treatment, 
with only hesperetin (8) and naringenin (9) inducing a significant increase following 10 µM treatment 
(1.72- and 1.53-fold respectively). Neither eriodictyol (10) nor homoeriodictyol (11) had a significant 
effect on ALP activity. 
  
 
Figure 2. The effects of dietary flavonoids and related phytochemicals on the osteogenic differentiation 
of hMSCs. Passage three MSCs were sub-cultured in osteogenic differentiation (Os.D) medium and 
treated with 0-10 µM phytochemicals at days 0, 3, and 6. Cultures were assayed for ALP activity and 
cell number at day 9. Values are expressed as means of percentage of untreated control from 3 
independent triplicate experiments with error bars representing SEM and asterisks representing 
significance compared to the vehicle control value (***p < 0.001; **p < 0.01; *p < 0.05). 
Phytochemical names corresponding to treatment numbers are displayed in Figure 1.  
 
Of the flavones tested in this study, diosmetin (12), apigenin (13) and flavone (14) had no effect on 
ALP activity at any concentration. Luteolin (15) induced a significant decrease in ALP activity 
following 10 µM treatment to approximately 0.59-fold of the VC. 
No flavanol tested significantly increased ALP activity at any concentration. Whilst (2R,3R)-
epicatechin (16) and (2R,3S)-catechin (17) had a negligible effect, (2R,3R)-epigallocatechin-3-O-
gallate (18) induced a significant decrease in ALP following 10 µM treatment to approximately 0.75-
fold of the VC. 
Of the related compounds tested, neither phloretin (19), (2R,3R)-taxifolin (20), nor resveratrol (21) 
had an effect on ALP activity at any concentration tested.    
  
     The Effect of Flavonoids on the Proliferation and Viability of hMSCs. Effects of treatments on 
cell number (Figure S1, Supporting Information) and viability (Table S2, Supporting Information) were 
also examined. Of the compounds tested, only kaempferol (2) and hesperetin (8) significantly increased 
cell number above the level of the VC. Four flavonols, four flavones, one flavanol, and the stilbene 
resveratrol decreased cell number. With the exception of the flavanols (2R,3R)-epicatechin (16) and 
(2R,3R)-epigallocatechin-3-O-gallate (18), no treatment significantly reduced cell viability suggesting 
anti-proliferative activity of a number of flavonoids, most notably within the flavone subclass with 
decreases in cell number as low as 0.43±0.05-fold of the VC.  
     QSAR Model Generation for the Relationship Between Flavonoid Structure and ALP Activity. 
Using 3D QSAR modelling with CoMFA, models were developed that predict the effect of 
phytochemical treatment at 5 and 10 µM concentrations on ALP activity in hMSC cultures. The 
training set consisted of ALP activity data (expressed as log10 ALP fold increase over the vehicle 
control) for 18 compounds (refer to Figure 1 for training set structures). Kaempferol (2), eriodictyol (10) 
and EGCG (18) data were removed to establish a test set. Both low-energy (built) conformers and 
PDB-extracted conformers (Table S2, Supporting Information) for each compound were aligned to 
flavone by overlapping atoms 1, 5-10 and 1′- 6′. This allowed a satisfactory superimposition of all 
major areas of the compound; importantly, B- and C-rings of flavonoids, where the majority of 
structural variation in the training set occurred (Figure 3). 
 
  
Figure 3. Alignment rule. Conformers were aligned by common core alignment to flavone, 
overlapping atoms 1, 5-10 and 1′- 6′ (shaded: panel A). This delivered an alignment with appropriate 
  
superimposition of flavonoid A-, B-, and C-rings (see lateral view: panel B), as well as directional 
alignment of functional groups (oxygen atoms of hydroxyl and methoxy groups highlighted in black). 
 
Statistical models were generated using partial least squares (PLS) regression analysis. Linear 
regression plots between observed activity within the training set and predicted activity based on 
molecular descriptors had a good correlation at both 5 µM (r2 = 0.768; Figure 4A, Table 1) and 10 µM 
(r2 = 0.767; Figure 4B, Table 1), signifying that variances in molecular fields account for 
approximately 77% of the variances in training set activity. Table S3, Supporting Information presents 
all CoMFA-generated values including residual values (mean observed value minus mean predicted 
value) and standard deviations of prediction between different conformers processed per compound. 
Both models had an optimum component number of 5 (Table 1).  
 
 
Figure 4. Linear correlation between observed and predicted values generated from CoMFA for ALP 
activity at 5 µM (A) and 10 µM (B). Observed values (x-axis) are correlated with CoMFA-generated 
predicted values based on steric and electrostatic field variations. Predicted values are expressed as the 
mean of all individual conformer predictions and numbers indicate compounds (as listed in Figure 1). 
Corresponding CoMFA-generated values are presented in Table S3, Supporting Information.   
  
 
Table 1. Partial Least Squares Analysis for CoMFA Models 
 r2 a q2 b SE c comp. d 
5 µM model 0.768 0.466 0.077 5 
10 µM model 0.767 0.420 0.098 5 
acorrelation coefficient; bcross-validated correlation coefficient; cstandard 
error for the prediction of log10(ALP fold change); dnumber of components 
used in CoMFA model. 
 
The predictive potential of the model was quantified using leave-one-out cross-validation. q2 values 
for 5 and 10 µM models were 0.466 and 0.420 with standard errors of prediction of 0.077 and 0.098 
respectively (Table 1). Although these appear low, the q2 value is a conservative estimate as its 
calculation involves removing data so true predictability can be underestimated.33 Therefore, models 
were further validated using a test set of molecules.    
     Test Set of Molecules for Model Validation. The test set consisted of three compounds with 
known activity (“known compounds”: kaempferol (2), eriodictyol (10) and EGCG (18)), previously 
removed from the training set, and three with unknown activity, (“blind compounds”: kaempferide  
(T1), pinocembrin (T2) and tricetin (T3)), which were predicted using the QSAR models and assayed 
in the model of osteoblast differentiation at a later date (see Figure 5 for structures).  
 
 
# compound R1 R2 R3 R4 
2 kaempferol OH H OH H 
10 eriodictyol - OH OH H 
18 EGCG (2R,3R) G. Ac. OH OH OH 
T1 kaempferide OH H OCH3 H 
T2 pinocembrin - H OH H 
T3 tricetin H OH OH OH 
Figure 5. Test Set Compound Structures. The structures and respective substituents (R-groups) of test 
compounds with known activity (2, 10 and 18) or unknown activity (T1, T2 and T3) are indicated. Numbers 
within skeletal structures represent atom nomenclature. 
  
 
QSAR model predictions for compounds with known activity correctly identified kaempferol (2) as 
being active, eriodictyol (10) as having a negligible effect and EGCG (18) as having a detrimental 
effect on ALP activity in hMSCs after 9 days in culture. Both 5 and 10 µM models are relatively 
conservative in their prediction of the level of ALP activity in response to kaempferol (2) with 
predicted values approximately 78% and 76% of the mean observed activity in cultures treated with 5 
and 10 µM kaempferol (2) respectively. Models also overestimated the detrimental effect of EGCG (18) 
with predicted activity approximately 1.9- and 2.6-fold lower than actual activity in 5 and 10 µM 
models respectively (Table 2).    
 
Table 2.  Known Test Set Predicted Values and Observed ALP Activity Values.  
# 5 µM model  10 µM model 
 obsd. d 
(%) 
pred. e  
(%) 
res. f 
(%) 
 obsd. d 
(%) 
pred. e  
(%) 
res. f 
(%) 
2 a 237* 185 52  268* 205 63 
10 b 98 110 -16  111 107 4 
18 c 84 44 40  75* 29 46 
akaempferol (2), beriodictyol (10), cEGCG (18). dobserved; epredicted; 
fresidual. *p<0.05 compared to control when tested experimentally.  
 
Of the blind compounds within the test set, kaempferide (T1) was predicted to increase ALP activity 
at 5 µM (180% of VC) and 10 µM (248% of VC), pinocembrin (T2) to have a slight detrimental effect 
on ALP activity at 5 µM (81% of VC) but negligible effects at 10 µM (96% of VC), and tricetin (T3) to 
decrease ALP activity at 5 and 10 µM (90% and 64% of VC respectively).  
 When tested experimentally, kaempferide (T1) increased ALP activity in hMSC cultures dose-
dependently with significant elevation following treatment with 1, 5 and 10 µM to 143±6%, 237±23% 
and 281±30% of the VC respectively (Figure 6). As with kaempferol (2), QSAR models 
underestimated activity, with predicted values 71% and 88% of the observed value in 5 and 10 µM 
models respectively (Table 3), but successfully identified an active compound. Pinocembrin (T2) had 
no significant effect on ALP activity at any concentration tested (Figure 6). Although the exact values 
  
for pinocembrin (T2) predicted by QSAR models are lower than actual values for ALP activity (Table 
3), the successful prediction of an inactive compound is highlighted. Finally, tricetin (T3), whilst 
having no significant effect on ALP activity at 1 or 5 µM, significantly decreased ALP activity 
following 10 µM treatment to a level of 79±7% of the VC (Figure 6). These predictions accurately 
described tricetin (T3) as a compound that has a detrimental effect on osteogenic differentiation at the 
higher concentration tested (Table 3).  
 
 
Figure 6. The effects of blind test compounds on the osteogenic differentiation of hMSCs. Passage 3 
MSCs were sub-cultured in Os.D medium and treated with 0-10 µM kaempferide (T1), pinocembrin 
(T2) and tricetin (T3) at days 0, 3, and 6. Cultures were assayed for ALP activity at day 9. Values are 
expressed as means of percentage of control from 3 independent triplicate experiments with error bars 
representing SEM and asterisks representing significance compared to the vehicle control value (***p 
< 0.001; *p < 0.05). 
 
Table 3. Blind Test Set Predicted Values for ALP activity. 
# 5 µM model  10 µM model 
 obsd. d 
(%) 
pred. e  
(%) 
res. f 
(%) 
 obsd. d 
(%) 
pred. e  
(%) 
res. f 
(%) 
T1 a 237* 170 67  281* 248 33 
T2 b 107 81 26  121 96 25 
T3 c 99 90 9  79* 64 15 
akaempferide (T1), bpinocembrin (T2) ctricetin (T3). dobserved; epredicted; 
fresidual. *p<0.05 compared to control when tested experimentally. 
 
  
In summary, QSAR models successfully predicted kaempferol (2) and kaempferide (T1) as being 
active, eriodictyol (10) and pinocembrin (T2) as having little effect, and EGCG (18) and tricetin (T3) 
as having little or a detrimental effect. The observed results follow these predictions, although 
estimates for active compounds in the test set are relatively conservative at both 5 and 10 µM 
(summarised in Figure 7A and C respectively). The linear correlation between observed and predicted 
activity for known and blind predictions is relatively good for 5 µM (r2=0.895) and 10 µM (r2=0.995) 
models (Figure 7B&D), demonstrating the predictive capacity of QSAR models.   
 
 
Figure 7. Correlation between observed and predicted activities in the test set. Observed and predicted 
values for the ALP activity of known and blind compounds (kaempferol (2), eriodictyol (10), EGCG 
(18), kaempferide (T1), pinocembrin (T2), tricetin (T3) are presented as percentage of vehicle control 
in response to 5 µM (A) and 10 µM treatment (C). The respective linear correlations between observed 
and predicted values are represented for the 5 µM (B) and 10 µM (D) QSAR models.  
 
     Examination of Structure-Activity Relationships.  CoMFA contour maps for 5 and 10 µM 
models were examined for regions where variations in steric and electrostatic molecular fields 
contribute to changes in training set compound activity. Maps for both models were essentially 
  
identical (inset Figure 8Ai), also reflected by the similarity in r2 values (0.768; 5 µM and 0.767; 10 
µM). Therefore, the following description of contours is considered applicable to both models. 
 
 
Figure 8. QSAR contour maps derived from CoMFA for ALP activity in response to flavonoid 
treatment. A: Contour maps representative of the most active compound: tamarixetin (1) (Ai & Aiii) 
and least active compound: luteolin (15) (Aii & Aiv) in the 10 µM training set. Inset figure represents 
contours for the 5 µM training set. B: Contour maps displaying the influence of a 2-C3-C double bond 
on conformation. Green and yellow contours highlight steric fields (green: steric bulk is favourable, 
yellow: steric bulk is unfavourable). Blue and red contours highlight electrostatic fields (blue: positive 
charge is favourable, red: negative charge is favourable). Contours are calculated as the model 
Stdev*Coeff. C: A summary of molecular regions, derived from CoMFA, important for the osteogenic 
activity of flavonoids; (I) steric bulk (shaded green) and electronegativity (shaded red) at the C-3 and 
  
C-4 positions of the C-ring; (II) unsaturation of the 2-C3-C of the C-ring (shaded grey) ensuring 
planarity; (III) an overall positive charge at the B-ring (shaded blue); (IV) steric bulk at the C-4ʹ 
position of the B-ring (shaded green); and (V) reduced steric bulk at the C-3ʹ and C-4ʹ positions of the 
B-ring (shaded yellow).  
 
Figure 8 presents the contour maps for the most active training set conformer: tamarixetin (1), and 
the least active conformer: luteolin (15). Steric fields (Figure 8Ai-ii) suggest that the largest region 
where steric bulk is favourable (green) is at the C-3 and C-4 positions of the C-ring. Contributing to 
steric bulk here is the hydroxyl group at the third carbon (OH-3), present in the flavonol tamarixetin 
(Figure 8Ai) but not in the flavone luteolin (Figure 8Aii). This region is also associated with a red 
contour suggesting negative charge is favourable, supporting the importance of the OH-3 group (Figure 
8Aiii-iv). The 3.1-, 2.8-, and 3.6-fold greater activity of the flavonols tamarixetin (1), kaempferol (2) 
and quercetin (4) compared to their respective flavone analogues diosmetin (12), apigenin (13) and 
luteolin (15) at 10 µM highlight the benefit of a OH-3. Also associated with these contours is the 
ketone group at the fourth position of the C-ring (oxo-4), although the only compounds without an oxo-
4 group (catechin (17) and epicatechin (18)) are non-planar due to 2-C3-C bond hydrogenation, so a 
direct comparison cannot be made.   
Indeed, a 2-C3-C double bond at the C-ring appears crucial for flavonol activity, as exemplified by 
the comparison of quercetin (4) with taxifolin (20). Whilst quercetin has a 2-C3-C double bond with 
associated planarity, taxifolin does not, resulting in flexibility and subsequent inactivity. An overlay of 
quercetin and taxifolin (purple) is displayed in Figure 8B showing the unfavourable conformation of 
taxifolin, with OH-3 and oxo-4 groups positioned away from regions of steric- and electronegative-
favourability. In the absence of a OH-3 group however, it appears favourable to have a hydrogenated 2-
  
C3-C bond as highlighted by the comparison of the flavanones hesperetin (8) and naringenin (9), both 
active at 10 µM, with the flavones diosmetin (12) and apigenin (13), both inactive at 10 µM.  
At the B-ring, there is a small steric-favourable region at the C-4′ position that corresponds well 
with the methoxy group present in tamarixetin (1) (Figure 8Ai) but not in luteolin (15) (Figure 8Aii). 
The benefit of C-4ʹ-methylation is supported by the 1.4-fold greater activity of tamarixetin (1) 
compared to quercetin (4) at 10 µM, and the high activity of the test compound kaempferide (T1). 
There is also a small steric-favourable region at the C-3′ position, likely associated with the plane that 
conformers are laying within contours, with the luteolin conformer’s OH-3ʹ being brought closer to the 
yellow unfavourable region (Figure 8Ai-ii). The steric-unfavourable contour at the 3′ position can be 
further associated with the detrimental effect of bulky substitution here as illustrated by the 1.4-fold 
lower activity of isorhamnetin (6) (OCH3-3ʹ) compared to quercetin (4) (OH-3ʹ) at 10 µM. Also 
unfavourable is steric bulk at the 5′ position of the B-ring (Figure 8Ai-ii), where substitution here (e.g. 
myricetin (7)) was associated with a low level of activity.  
Also at the B-ring, there is a large blue contour covering the 3′, 4′ and 5′ positions: a region where 
positive charge is favourable for activity whereas negative charge is unfavourable. This is highlighted 
by comparing the most active (Figure 8Aiii) and least active (Figure 8Aiv) compounds in the training 
set, where an OH-3′, OCH3-4′ configuration conveys better activity than OH-3′, OH-4′ substitution. A 
similar relationship occurs within flavonol and flavanone subclasses (i.e. tamarixetin (1) > quercetin 
(4); hesperetin (4) > eriodictyol (10)). Multiple hydroxylation at the B-ring was associated with the 
attenuation of activity as exemplified by myricetin (7), EGCG (18), and tricetin (T3) where hydroxyl 
groups at 3′, 4′ and 5′ positions, conveying strong electronegativity, were unfavourable for activity.  
In addition to contours at the C and B rings, there are also steric-favourable and unfavourable 
regions at the fifth and seventh positions of the A-ring (Figure 8Ai-ii). The majority of compounds 
within the training set were hydroxylated at these positions so this is likely due to compound flexibility. 
  
This is illustrated by the comparison of quercetin (4) with its non-planar analogue taxifolin (20) (Figure 
8B); where the OH-7 of quercetin is closer to the steric favourable region, the OH-7 and OH-5 of 
taxifolin are closer to steric unfavourable regions.   
CoMFA reveals two major molecular regions that contribute to osteogenic activity within the 
training set (Figure 8C). Perhaps the most important is at the C-ring, with OH-3 and oxo-4 groups 
conveying favourable steric bulk and electronegativity, as well as an unsaturated 2-C3-C bond 
resulting in planarity. These characteristics are common to flavonols which exhibited the greatest 
activity within the training set. The second major region is at the B-ring, where steric bulk is 
unfavourable at all positions except from the 4′ position where bulky substitution may be favourable. 
Accompanied with this is an overall positive charge of the B-ring suggesting that multiple 
hydroxylation is unfavourable for activity. Although the exact target(s) for flavonoids in our model of 
osteoblast differentiation are unknown, these variances in steric and electrostatic interactions are likely 
to govern binding affinity to target protein(s) and subsequently effect their biological activity.34 
Conclusions. Seven flavonols (tamarixetin (1), kaempferol (2), kaempferide (T1), galangin (3), 
quercetin (4), fisetin (5), and isorhamnetin (6)) and two flavanones (hesperetin (8) and naringenin (9)) 
were found to significantly augment ALP activity in hMSC cultures here for the first time. All other 
compounds belonging to flavones, flavanols, dihydroflavonols, dihydrochalcones or stilbenes did not 
significantly increase ALP activity above the vehicle control. 
Although many of the compounds tested in our model have previously been investigated for their 
effect on osteoblastogenesis, outcomes have been highly variable (summarised in Table S1, Supporting 
Information), demonstrating the requirement for comprehensive screening within a single model. 
Through executing this, valuable insights have been realised with respect to the molecular properties of 
flavonoids that convey osteogenic activity in hMSC cultures. The consistent effects of flavonols in our 
model corroborate the promising observations of kaempferol (2) and quercetin (4) increasing 
  
osteogenic differentiation in vitro10-14. This, accompanied by the osteogenic effects of the two flavonols 
in in vivo models,10, 13, 15-21 highlights an excellent potential for dietary flavonoids belonging to this 
subclass to promote skeletal health, either by maximising bone mass accrual during growth, or 
modulating skeletal homeostasis throughout life, thus reducing the lifetime risk of fragility fractures.2 
We have also demonstrated the capacity for QSAR models to predict the osteogenic activity of 
compounds; detailing their potential for the prediction of other flavonoids and related compounds with 
unknown activity, and also for the lead development of novel bone-anabolic treatments. Natural 
products have been the source of lead compounds for the development of drugs targeted at a number of 
conditions.35 Gaining an understanding of the key molecular regions of flavonoids that convey pro-
osteogenic activity forms a basis to make analogues with improved pharmacological and/or 
pharmacokinetic properties. The predominant treatments for osteoporosis are the anti-resorptive 
bisphosphonates, and although in recent times new bone-anabolic treatments have been developed, 
these are associated with numerous side-effects36 highlighting the continued need for better anabolic 
treatments for bone-metabolic disorders.  
   
EXPERIMENTAL SECTION (full methods available in Supporting Information Methods) 
     Human Mesenchymal Stem Cell (hMSC) Culture. To assess the impact of test compounds on 
osteoblast differentiation, proliferation and cell viability, hMSCs, derived from bone marrow aspirates 
of healthy donors, were cultured at high density in media containing osteogenic supplements (Os.D 
medium) prior to treatment with test compounds or controls.   
     Phytochemicals. Of the 24 purchased phytochemicals examined in this study, 22 were determined 
by HPLC to be ≥95% pure and two were ≥90% pure. All solubilised phytochemicals were serially 
diluted in Os.D medium to achieve test compound concentrations of 10, 5 and 1 µM. Treated wells 
were adjusted to have a final concentration of 0.1% (v/v) DMSO and all assays also included a vehicle 
  
control (0.1% (v/v) DMSO only), a positive control (50 nM calcitriol) and an untreated control. All 
tests within individual experiments were performed in triplicate. Treated cultures were maintained for 
nine days with media changes and re-application of compounds every three days.  
     Determination of Osteogenic Differentiation (ALP activity), Cell Number and Viability. 
Cultures were assessed for ALP activity and cell number on day 9, a time point in our model found to 
be optimal for minimal variability, and for cell viability on days 1, 4, and 7 (24 hours after every 
treatment). ALP activity was determined using the para-nitrophenyl phosphate-based colorimetric 
method as described in 37, and data was normalised to time and cell number (µM pNP/min/20,000 
cells). Cell number was determined using the methylene blue-based proliferation assay as described in 
38 and cell viability was determined using the Alamar blue cytotoxicity assay as described in 39. All data 
were expressed as the percentage of the untreated control value.  
     Quantitative Structure-Activity Relationship (QSAR) Study. Three-dimensional (3D) QSAR 
models were developed using SYBYL-X (v1.3) molecular modelling software (Tripos). CoMFA 
descriptors were selected to correlate steric and electrostatic field energy variations with ALP activity 
in response to 5 and 10 µM treatments. The training set of compounds consisted of 18 phytochemicals 
with their associated biological activity and the predictive capacity of models was validated using a test 
set of six compounds.  
     Statistical Analyses. Statistical analysis was carried out using GraphPad Prism (v4.00). Data are 
expressed as means of percentage of the untreated control from three independent triplicate 
experiments ± standard error of the mean (SEM). Statistical comparisons were made using one-way 
Analysis of Variance (ANOVA; ALP activity and cell number) or two-way ANOVA (cell viability) 
followed by Bonferroni post hoc tests. P-values < 0.05 between treatments and the vehicle control were 
considered significant (*p < 0.05; **p < 0.01; ***p < 001). For 3D QSAR, statistical analyses were 
  
generated using SYBYL-X (v1.3) (Tripos), and regression models produced using PLS analysis with 
leave-one-out cross-validation. 
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